Recent Advances in Osteoarthritis: Pathophysiology, Diagnosis, and Therapeutic Strategies

Zulekha Ali[1], Shalini Sharma[1], Shabnam Ain[2*], Qurratul Ain[2], Babita Kumar[2]

[1]SDGI GLOBAL UNIVERSITY (SGU), NH-9, Delhi-Hapur Road, Ghaziabad, Delhi-NCR, Dasna, Pin Code-201015, U.P.
[2]Department of Pharmaceutics, Sanskar College of Pharmacy and Research, Ghaziabad-201302, Uttar Pradesh, India
Address for Correspondence: **Dr. Shabnam Ain**
Head of Department, Sanskar College of Pharmacy and Research,
Jindal Nagar, Ghaziabad, Utter Pradesh-201302 India
Email: shabnam.ain@sanskar.org
Phone No. + 91-9310807567

Abstract
Osteoarthritis (OA) is a chronic, degenerative joint disease that affects millions of people worldwide, representing a major cause of disability, particularly in aging populations. Characterized by progressive cartilage breakdown, subchondral bone changes, and synovial inflammation, OA severely impacts joint function and quality of life. Despite significant research efforts, effective disease-modifying treatments remain elusive, and current therapies primarily focus on symptomatic relief rather than halting or reversing disease progression. Recent advances in understanding the molecular and cellular mechanisms underlying OA have provided new insights into its pathophysiology, which includes altered chondrocyte function, extracellular matrix degradation, and inflammatory cytokine signaling. Genetic predispositions, mechanical stress, and environmental factors such as obesity and joint injury play key roles in the disease's onset and progression. Emerging biomarkers for OA diagnosis and prognosis hold promise for earlier detection and personalized treatment approaches. Diagnostic innovations, particularly imaging techniques like magnetic resonance imaging (MRI) and biomarkers that detect early structural changes, are enhancing our ability to identify OA at its onset and monitor its progression. In terms of therapeutic strategies, while pharmacologic interventions like nonsteroidal anti-inflammatory drugs (NSAIDs) and intra-articular injections offer symptom relief, there is increasing interest in regenerative medicine, including stem cell therapies, gene therapies, and tissue engineering approaches aimed at cartilage regeneration and slowing disease progression. Moreover, biologic agents targeting specific inflammatory pathways are being explored in clinical trials, offering hope for more effective treatments. This review highlights recent advancements in OA pathophysiology, diagnostic innovations, and emerging therapeutic strategies, emphasizing the importance of personalized medicine in managing this debilitating disease. As we move forward, a deeper understanding of OA's molecular underpinnings is expected to lead to more targeted and effective treatments.
Keywords: Osteoarthritis, pathophysiology, diagnosis, therapeutic strategies, regenerative medicine, cartilage degeneration, inflammation.

1. Introduction

Osteoarthritis (OA) is a prevalent, chronic, and debilitating disease that affects millions of individuals globally. It is considered the most common form of arthritis and a leading cause of disability in both developed and developing nations. OA is characterized by progressive degeneration of articular cartilage, subchondral bone remodeling, synovial inflammation, and alterations in the extracellular matrix (ECM) of the joint. This multifactorial condition primarily

impacts weight-bearing joints, including the knee, hip, and spine, leading to pain, stiffness, functional impairment, and a significant decline in the quality of life. As the global population ages, the prevalence of OA continues to rise, further underscoring its status as a major public health challenge (O'Neill and Felson, 2018). OA imposes a substantial economic burden on society due to direct medical costs, including healthcare services, hospitalizations, and pharmaceutical treatments, as well as indirect costs such as lost productivity and long-term disability (Rabiei et al., 2021). The World Health Organization (WHO) estimates that OA affects more than 300 million people worldwide, and it is projected that this number will increase dramatically in the coming decades due to the aging population, rising obesity rates, and greater life expectancy. The economic impact of OA is compounded by its association with comorbidities such as cardiovascular disease, diabetes, and depression, which further exacerbate the overall healthcare burden. Consequently, OA represents a significant strain on healthcare systems globally, highlighting the urgent need for effective preventive and therapeutic strategies (Prevention, 2018).

The pathophysiology of OA is complex, involving the interplay of genetic, biomechanical, and environmental factors. Cartilage degradation, chondrocyte dysfunction, and subchondral bone changes are central to the disease process. These alterations lead to the progressive loss of joint function and the characteristic clinical symptoms of pain, joint stiffness, and reduced range of motion. The underlying mechanisms include abnormal extracellular matrix turnover, increased production of inflammatory cytokines (e.g., interleukin-1, tumor necrosis factor-alpha), and the release of matrix-degrading enzymes such as matrix metalloproteinases (MMPs) and aggrecanases (Mobasheri and Batt, 2016). While the progression of OA can vary between individuals, the disease remains largely irreversible, with no current therapeutic strategies that can halt or reverse cartilage loss and joint degeneration. Despite substantial advancements in our understanding of the molecular mechanisms underlying OA, the development of disease-modifying therapies (DMOADs) has remained elusive. Current treatments primarily focus on symptom management rather than altering the disease course. Nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, and opioid analgesics are commonly used to manage pain, while physical therapy and weight management play important roles in improving joint function and reducing symptoms. Intra-articular injections of corticosteroids, hyaluronic acid, and platelet-rich plasma (PRP) are also frequently employed to provide temporary relief from inflammation and joint pain. However, these therapies offer limited long-term benefits and do not address the underlying pathophysiological processes that drive disease progression (Köhler-Forsberg et al., 2017; Sobhani et al., 2023).

Surgical interventions, such as joint replacement, remain a treatment option for advanced OA, particularly in cases of end-stage joint degeneration. However, these procedures are associated with significant risks, including infection, blood clots, and the need for revision surgeries, and are generally reserved for patients with severe disability. Moreover, surgical options are often not feasible for younger individuals or those with early-stage OA, leaving a significant unmet need for more effective, disease-modifying treatments (Watson et al., 2021). The lack of disease-modifying treatments highlights one of the primary challenges in OA management. While numerous pharmacological and biological agents are being investigated in clinical trials, few have demonstrated substantial efficacy in altering disease progression. Moreover, the heterogeneity of

OA, both in terms of its pathophysiology and clinical presentation, further complicates the development of universally effective therapies. Personalized medicine, based on genetic profiling, biomarkers, and patient-specific factors, holds promise in addressing these challenges by enabling more targeted and individualized therapeutic approaches (Traut, 2022). However, significant hurdles remain in translating preclinical discoveries into clinical practice, and further research is required to identify biomarkers for early diagnosis, better predict disease outcomes, and develop effective, long-term treatments that can modify the course of OA (Anthony et al., 2022).

Osteoarthritis is a major public health issue with profound implications for individuals, healthcare systems, and society at large. The absence of disease-modifying treatments, combined with the growing burden of OA, underscores the urgent need for continued research into the pathophysiology, diagnosis, and therapeutic options for this debilitating condition (Kangeswari et al., 2021). As we move towards a more personalized approach to OA management, the hope is that emerging therapies, including regenerative medicine, biologics, and novel pharmacological agents, will offer more effective options for patients, ultimately improving outcomes and reducing the burden of this debilitating disease (Hunter et al., 2002).

2. Pathophysiology of Osteoarthritis

Osteoarthritis (OA) is a multifactorial, degenerative joint disease primarily characterized by the progressive deterioration of articular cartilage, subchondral bone remodeling, synovial inflammation, and changes in the extracellular matrix (ECM). It is the most prevalent form of arthritis and a leading cause of disability, especially in aging populations (Mobasheri and Batt, 2016). Understanding the pathophysiology of OA has significantly advanced in recent years, uncovering intricate molecular and cellular mechanisms that contribute to the onset and progression of the disease. This section aims to provide a detailed exploration of the recent advances in the molecular and cellular understanding of OA, with a focus on cartilage degradation, inflammation, subchondral bone changes, and chondrocyte dysfunction (Ali, 2021).

At the molecular level, OA is primarily driven by an imbalance between catabolic and anabolic processes within the joint. This imbalance results in the breakdown of cartilage, particularly the depletion of proteoglycans such as aggrecan, and the degradation of collagen fibers, especially type II collagen. The loss of cartilage integrity is largely mediated by matrix metalloproteinases (MMPs), aggrecanases, and other enzymes that degrade the ECM (Kucharz et al., 2016). Recent studies have shown that MMP-13 is a key player in the degradation of type II collagen, and its upregulation is associated with the progression of OA. Additionally, the activity of aggrecanases, including ADAMTS-4 and ADAMTS-5, has been closely linked to cartilage degradation, as these enzymes specifically cleave aggrecan, a vital component of cartilage (Stanciugelu et al., 2022).

Chondrocytes, the only cell type within articular cartilage, play a central role in OA pathophysiology. In a healthy joint, chondrocytes maintain cartilage homeostasis by balancing the synthesis and degradation of the ECM. However, in OA, chondrocytes undergo phenotypic changes, including hypertrophy, apoptosis, and altered anabolic and catabolic activity (Zheng et al., 2021). Recent findings have indicated that chondrocytes in OA adopt a more inflammatory and

catabolic phenotype, characterized by the increased production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6), which in turn enhance the expression of MMPs and aggrecanases, further exacerbating cartilage degradation. Moreover, the disruption of the autophagic process in chondrocytes has been implicated in OA progression, as impaired autophagy can lead to the accumulation of damaged cellular components and contribute to cellular dysfunction (Mimpen et al., 2021).

The role of inflammation in OA has been well-documented, with synovial inflammation playing a pivotal role in disease progression. OA is often considered a "low-grade" inflammatory condition, where the synovium becomes infiltrated by immune cells such as macrophages, T-cells, and neutrophils (Coaccioli et al., 2022; Mehrani et al., 2023). These immune cells release inflammatory mediators, including cytokines (e.g., IL-1, TNF-α), prostaglandins, and chemokines, which not only perpetuate cartilage degradation but also induce pain and stiffness associated with OA. Recently, studies have highlighted the involvement of the NLRP3 inflammasome in the pathogenesis of OA, as its activation leads to the release of IL-1β, a key cytokine involved in both cartilage degradation and synovial inflammation. Another critical aspect of OA pathophysiology is the remodeling of subchondral bone (Rizzo et al., 2023). In OA, subchondral bone undergoes a series of changes, including sclerosis, osteophyte formation, and the development of bone marrow lesions. These changes are thought to result from mechanical stress and the release of pro-inflammatory cytokines from the damaged cartilage and synovium. Recent research has focused on understanding the molecular signaling pathways involved in subchondral bone remodeling, particularly the role of the Wnt/β-catenin signaling pathway and the RANK/RANKL/OPG system. The Wnt/β-catenin pathway is implicated in both cartilage degradation and bone remodeling, while the RANK/RANKL/OPG pathway plays a critical role in osteoclastogenesis and bone resorption in OA (Gao et al., 2020).



Figure 1: This diagram illustrates the pathology of osteoarthritis (OA), highlighting the key cellular and molecular events that contribute to joint degeneration. The process begins with mechanical stress, injury, or infection (1), leading to the release of alarmins such as 14-3-3e (2), which bind to pattern-recognition receptors (PRRs) on immune cells like macrophages (3). These interactions activate inflammatory pathways, resulting in the polarization of cells into a catabolic phenotype (4) and the release of pro-inflammatory mediators (5) such as TNFα, MCP1, and IL-6. This cascade ultimately leads to cartilage degradation, joint inflammation, and bone remodeling (6), which are central features of OA pathogenesis. The involvement of various cell types, including osteoclasts, macrophages, fibroblasts, and chondrocytes, plays a crucial role in the progression of OA.

Additionally, emerging studies have highlighted the involvement of oxidative stress in OA pathophysiology. Oxidative reactive oxygen species (ROS) stress, resulting from an imbalance between the productions of reactive oxygen species (ROS) and antioxidant defenses, is known to induce chondrocyte apoptosis, ECM degradation, and inflammation (Tudorachi et al., 2021). Recent studies have also suggested that the mitochondrial dysfunction in chondrocytes may be a key driver of oxidative stress and cellular dysfunction in OA. The pathophysiology of osteoarthritis is a complex and multifaceted process involving molecular, cellular, and tissue-level alterations. Advances in the understanding of OA have shed light on the intricate interactions between cartilage degradation, synovial inflammation, subchondral bone remodeling, and chondrocyte dysfunction. These discoveries have opened new avenues for therapeutic interventions, including the development of targeted biologics and gene therapies aimed at modulating these pathological

processes. Further research is needed to fully elucidate the molecular mechanisms underlying OA and to translate these findings into more effective disease-modifying treatments (Mehrani et al., 2023).

3. Diagnosis of Osteoarthritis

Osteoarthritis (OA) is a multifactorial, degenerative joint disease primarily characterized by the progressive breakdown of articular cartilage, subchondral bone remodeling, and synovial inflammation. It is the leading cause of disability in adults, with its prevalence increasing due to the aging population and rising rates of obesity (Dudaric et al., 2023). Timely and accurate diagnosis of OA is crucial for effective management, particularly in the early stages when interventions may slow or even halt disease progression. Over the past decade, significant advances have been made in OA diagnosis, ranging from enhanced imaging techniques to the discovery of novel biomarkers that provide deeper insights into disease pathophysiology and progression (Jang et al., 2021).

Clinical Diagnosis and Grading of osteoarthritis

Traditional diagnosis of OA has been based on clinical evaluation, which includes a comprehensive assessment of symptoms such as joint pain, stiffness, swelling, and functional limitations. Clinicians often rely on the physical examination, patient history, and assessment scales like the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) to evaluate the severity of symptoms. While these methods remain fundamental, they are limited in detecting early-stage OA when structural changes are not yet apparent (Linda Pertiwi and Jaya Kirana, 2023). The Kellgren-Lawrence (KL) grading system has long been used to assess the radiographic severity of OA, categorizing the disease into five grades based on the degree of joint space narrowing, osteophyte formation, and subchondral bone sclerosis (Neubauer et al., 2023). However, this approach fails to detect early biochemical or histological changes in cartilage and may miss subtle disease manifestations in the pre-radiographic stages (Tiulpin et al., 2018).

Imaging Innovations of osteoarthritis

Advancements in imaging technologies have revolutionized OA diagnosis by providing more detailed insights into joint structure and function. While X-ray remains a widely used tool for diagnosing advanced OA, newer imaging modalities such as magnetic resonance imaging (MRI) and ultrasound have gained prominence for their ability to detect early structural changes before they become apparent on conventional radiographs. MRI, in particular, has emerged as a gold standard in evaluating OA, enabling the visualization of soft tissues, cartilage thickness, bone marrow lesions, and synovial inflammation (Paradis, 2021). The use of high-resolution MRI sequences like T2 mapping, dGEMRIC (delayed gadolinium-enhanced MRI of cartilage), and contrast-enhanced MRI can identify biochemical changes in cartilage and bone at a much earlier stage. MRI-based techniques also allow for the assessment of joint inflammation and can provide quantitative data on cartilage volume loss, which is a critical indicator of disease progression. Furthermore, functional MRI and dynamic contrast-enhanced MRI are being explored as tools for assessing the metabolic activity of cartilage, which could enable early detection of joint

degradation before structural changes occur (Banjar et al., 2022; Emanuel et al., 2022). Ultrasound imaging, due to its accessibility, real-time imaging capabilities, and relatively low cost, is also increasingly used to assess synovial inflammation, effusion, and osteophyte formation in OA. Advanced ultrasound techniques such as power Doppler have been shown to detect subtle synovial changes associated with inflammation, even in asymptomatic patients. Although ultrasound does not provide the same level of detail as MRI in evaluating cartilage, it remains an important tool for early diagnosis and monitoring disease progression, especially in regions where MRI facilities are not readily available (Mills et al., 2022; Wu and Chen, 2021).

Biomarkers for Early Diagnosis and Disease Monitoring of osteoarthritis

In addition to imaging advancements, significant progress has been made in identifying biomarkers for OA. These biomarkers hold promise for non-invasive early diagnosis, risk stratification, and monitoring disease progression. Biomarkers can be classified into two major categories: diagnostic biomarkers and progression biomarkers (Blanco, 2014; Kumar et al., 2020). Diagnostic biomarkers help identify the presence of OA, while progression biomarkers are used to track the severity and course of the disease over time. Several biomarkers of cartilage degradation, including aggrecan fragments**,** collagen type II cleavage products, and cartilage oligomeric matrix protein (COMP), have been investigated as potential diagnostic tools (Shih et al., 2023). For example, the presence of elevated levels of C-telopeptide of type II collagen (CTX-II) in synovial fluid and blood is associated with cartilage degradation and may serve as a diagnostic marker for OA. Similarly, the use of matrix metalloproteinases (MMPs), which are enzymes that break down collagen and other components of the extracellular matrix, is being explored as a means to assess cartilage turnover and predict disease progression (Kumavat et al., 2021; Sadri et al., 2021).

Additionally, inflammatory biomarkers such as interleukins (IL-1, IL-6), tumor necrosis factor-alpha (TNF-α), and C-reactive protein (CRP) are being evaluated for their role in the pathogenesis of OA and their potential to predict flare-ups and disease progression (Nieboer et al., 2023). Elevated levels of these markers in the serum and synovial fluid of OA patients correlate with joint inflammation and disease severity. Advanced proteomic techniques, including mass spectrometry and protein arrays, are expected to facilitate the identification of novel biomarkers with improved sensitivity and specificity for early OA diagnosis (Amano et al., 2018; Kardos et al., 2019).



Figure 2: Comprehensive overview of physiological risk factors, molecular alterations, and their interactions contributing to joint degeneration and osteoarthritis. Key physiological risk factors include age, gender, genetic predisposition, obesity, joint injury, muscle weakness, and joint misalignment. Molecular alterations involve signaling pathways (e.g., NF-κB, RANKL, MAPK), inflammatory mediators (e.g., TNF-α, IL-1), metabolic changes (e.g., leptin, MMPs), and markers of cartilage and bone turnover. The schematic highlights pathological features like osteophyte formation, subchondral sclerosis, proteoglycan degradation, inflammation, and cartilage destruction, emphasizing their role in joint pain, stiffness, and lifestyle disturbances.

Genetic and Molecular Diagnostic Approaches of osteoarthritis

Recent advancements in molecular biology have also paved the way for genetic and epigenetic profiling of OA. Identifying genetic variations associated with OA susceptibility and progression could provide more precise diagnostic methods, particularly in individuals with a family history of the disease (Fan et al., 2024). Studies have identified several risk genes, including those involved in collagen synthesis and cartilage turnover, such as COL2A1**,** GDF5**,** and ADAMTS5**.** These genetic markers, in combination with clinical and imaging data, may enable the development of personalized diagnostic tools and targeted therapeutic strategies. OA has advanced significantly with the integration of advanced imaging techniques and the identification of novel biomarkers. MRI and ultrasound now offer early and non-invasive means to detect OA-related structural changes, while biomarkers are providing valuable insights into disease mechanisms and progression. As research continues to uncover more genetic and molecular insights into OA, it is likely that diagnostic approaches will become more personalized and precise. These innovations

not only promise to improve early detection and disease monitoring but also pave the way for more effective, targeted interventions aimed at slowing or halting disease progression. The future of OA diagnosis lies in the synergy between clinical evaluation, imaging, molecular diagnostics, and personalized medicine (Kim et al., 2023).

4. Current Therapeutic Strategies for Osteoarthritis

Osteoarthritis (OA) is a chronic, progressive musculoskeletal disorder characterized by the degeneration of articular cartilage, subchondral bone remodeling, synovial inflammation, and ultimately, the loss of joint function. This condition predominantly affects weight-bearing joints such as the knee, hip, and spine, and is a leading cause of disability globally (Panikkar et al., 2021). Despite its significant impact on quality of life, the management of OA remains complex and primarily palliative, as there are no disease-modifying treatments (DMTs) that can halt or reverse disease progression. Recent advances in OA treatment strategies have focused on improving symptom control, slowing disease progression, and exploring novel regenerative therapies. This section reviews the current therapeutic approaches for OA, with an emphasis on pharmacological interventions, surgical options, and emerging regenerative strategies (Motta et al., 2023; Yao et al., 2023).

Pharmacological Therapies

Pharmacological management of OA is primarily aimed at alleviating pain and improving joint function, as well as reducing inflammation. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most commonly used pharmacologic agents to manage OA pain. They act by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), which are involved in the synthesis of prostaglandins, mediators of pain and inflammation. However, long-term use of NSAIDs is often limited due to adverse gastrointestinal, renal, and cardiovascular effects. Acetaminophen is another first-line analgesic, though it lacks anti-inflammatory properties (Costa et al., 2023). For moderate to severe pain, opioid analgesics may be prescribed, but their use is often restricted due to concerns about dependence and side effects. Intra-articular corticosteroid injections are a widely used treatment modality in OA, providing short-term relief by reducing joint inflammation. However, repeated use may lead to cartilage degradation, and the benefits are typically transient. Hyaluronic acid (HA) injections, also known as viscosupplementation, have been employed to restore the viscoelastic properties of synovial fluid, enhancing lubrication and reducing friction in the joint. The efficacy of HA remains a topic of debate, with some studies showing modest benefit and others reporting limited or no long-term improvements (Ghouri and Conaghan, 2019).

Disease-Modifying Osteoarthritis Drugs (DMOADs)

The search for DMOADs, which can alter the course of OA by preventing or slowing cartilage degradation, remains a major focus of OA research. Several potential candidates are being explored, including biologics, growth factors, and small molecules. Among these, the use of glucosamine and chondroitin sulfate supplements has been studied extensively, with some evidence suggesting that they may reduce symptoms and slow the progression of joint damage. However, the clinical efficacy of these compounds remains controversial (Kim et al., 2022). Other

investigational drugs target specific molecules involved in cartilage breakdown, such as matrix metalloproteinases (MMPs) and aggrecanases, which degrade the extracellular matrix. A promising approach involves the inhibition of the interleukin-1 (IL-1) pathway, which plays a pivotal role in the inflammatory processes that drive OA. Biological agents targeting IL-1 (e.g., anakinra) and tumor necrosis factor-alpha (TNF-α) have shown efficacy in early-stage clinical trials, but their use has not been widely adopted in clinical practice due to variable results and potential safety concerns (Oo and Hunter, 2022; Shavlovskaya et al., 2023).

Surgical Interventions

Surgical options are typically considered when conservative treatments fail to provide sufficient relief or when joint function is significantly compromised. Arthroscopic procedures, including debridement and lavage, aim to remove damaged tissue and smooth rough cartilage surfaces, offering temporary symptomatic relief in some patients. However, these procedures have not been shown to modify the underlying disease process, and their efficacy remains limited (Bin et al., 2023). Joint replacement surgery, particularly total knee and hip arthroplasty (TKA and THA), remains the gold standard for end-stage OA, offering substantial improvements in pain and function. These procedures are typically recommended when conservative measures fail and the joint is severely damaged. While highly effective, joint replacement surgery is associated with risks such as infection, blood clots, and implant failure, and its success is often influenced by factors such as patient age, comorbidities, and surgical technique (Lim et al., 2023; Nishimura et al., 2021).

Regenerative and Experimental Therapies

In recent years, there has been growing interest in regenerative medicine as a potential strategy to repair or replace damaged cartilage and slow disease progression in OA. Stem cell-based therapies, including mesenchymal stem cells (MSCs), are being investigated for their potential to promote cartilage regeneration and modulate the inflammatory environment. Preclinical and early clinical studies have shown promising results, though the long-term efficacy and safety of stem cell therapies in OA remain to be fully established. Platelet-rich plasma (PRP) therapy, which involves the injection of concentrated platelets derived from the patient's own blood, is another promising regenerative approach (Abu-Seida, 2015). The growth factors in PRP are thought to stimulate tissue repair, reduce inflammation, and promote healing of damaged cartilage. While the evidence for PRP efficacy in OA is mixed, some studies have demonstrated moderate improvements in pain and function, especially in the knee. Tissue engineering strategies are also being explored as a means to develop more durable and functional cartilage replacements. These approaches often involve the use of scaffolds, biomaterials, and growth factors to promote the regeneration of cartilage in situ. Current challenges in tissue engineering for OA include the complexity of cartilage tissue regeneration, integration with surrounding tissue, and long-term durability of engineered constructs. Although significant progress has been made in understanding the pathophysiology of OA, current therapeutic strategies remain largely focused on symptom management rather than addressing the underlying causes of disease progression (Niu et al., 2023; Sun et al., 2021). Pharmacological treatments, surgical interventions, and emerging regenerative

therapies offer varying degrees of benefit, but no single approach can fully address the multifaceted nature of OA. Ongoing research into the molecular mechanisms of OA, along with the development of more targeted, personalized treatment strategies, holds the potential to improve outcomes for patients suffering from this debilitating condition. Further investigation into regenerative therapies, biologics, and disease-modifying drugs is crucial to the future management of OA, aiming to slow or halt disease progression and improve the quality of life for affected individuals (Chen, 2022).

5. Emerging and Experimental Therapies

Osteoarthritis (OA) is a chronic, degenerative joint disorder primarily characterized by the progressive breakdown of articular cartilage, subchondral bone remodeling, and synovial inflammation. Despite the substantial clinical and economic burden of OA, effective disease-modifying therapies that can halt or reverse the disease remain largely elusive. The current therapeutic strategies predominantly focus on symptom management, including pain relief and improving joint function (Goldring and Berenbaum, 2015; Pérez Fraile et al., 2023). However, recent advancements in research have led to the development of novel, experimental treatment modalities aimed at addressing the underlying pathophysiological mechanisms of OA. This includes emerging therapies in regenerative medicine, biologics, and targeted molecular therapies. These therapeutic approaches are promising, with the potential to modify disease progression and ultimately restore joint integrity (Schulze-Tanzil, 2021).

Regenerative Medicine in OA Therapy

Regenerative medicine represents one of the most exciting frontiers in OA treatment. The goal of regenerative therapies is to repair or regenerate damaged tissues, particularly articular cartilage, which has limited inherent healing capacity. Among the various regenerative strategies, stem cell-based therapies have garnered considerable attention. Mesenchymal stem cells (MSCs), which can be derived from bone marrow, adipose tissue, and synovium, have shown potential for cartilage repair due to their ability to differentiate into chondrocytes, secrete extracellular matrix components, and modulate local inflammation (Burke et al., 2016). Clinical trials assessing the intra-articular injection of MSCs have demonstrated variable outcomes, but recent studies suggest that combining MSCs with other bioactive agents or scaffolds may enhance their efficacy in cartilage regeneration. In addition to stem cell therapy, platelet-rich plasma (PRP) has emerged as an alternative regenerative approach. PRP, which is derived from autologous blood, contains a high concentration of growth factors that promote tissue healing and regeneration. The role of PRP in OA has been explored in numerous clinical trials, with mixed results; however, growing evidence suggests that PRP may have a beneficial effect in reducing pain and improving joint function in patients with mild to moderate OA, particularly in knee joints (Gherghel et al., 2023; Mayet et al., 2023).

Gene Therapy and Molecular Approaches

Gene therapy offers another innovative approach to treating OA by directly targeting the molecular pathways involved in cartilage degeneration. The objective of gene therapy in OA is to introduce

therapeutic genes that can modify the inflammatory and degenerative processes that contribute to disease progression (Salman et al., 2023). Several experimental strategies involve the delivery of genes encoding anabolic factors such as transforming growth factor-beta (TGF-β)**,** insulin-like growth factor (IGF), and bone morphogenetic proteins (BMPs**)** to promote cartilage formation and inhibit catabolic enzymes that degrade the extracellular matrix. Furthermore, the use of RNA-based therapies such as small interfering RNA (siRNA) or antisense oligonucleotides to silence pro-inflammatory cytokines like TNF-α or IL-1β represents an exciting avenue for targeted OA treatment. These molecules, when delivered locally to the affected joint, could potentially downregulate the inflammatory processes responsible for cartilage breakdown and pain (Schrenker et al., 2019).

Biologic Therapies

Biologic therapies are another promising avenue for OA treatment, particularly in targeting the inflammatory pathways that drive cartilage degradation and joint damage. Monoclonal antibodies and biological response modifiers have been designed to target specific molecules involved in OA pathophysiology. For example, interleukin-1 (IL-1) inhibitors such as anakinra have been studied for their ability to block the IL-1 pathway, which plays a crucial role in the inflammatory response and cartilage destruction in OA (Weber et al., 2021). Clinical trials have shown that IL-1 blockade can lead to improvements in pain and function in patients with OA, although the results have been somewhat inconsistent. Tumor necrosis factor-alpha (TNF-α) inhibitors, another class of biologics commonly used in autoimmune diseases, have also been evaluated in OA, with varying degrees of success. Despite their effectiveness in diseases like rheumatoid arthritis, the use of TNF inhibitors in OA has faced challenges, primarily due to the complex, multifactorial nature of OA pathogenesis and the need for more targeted therapies (Delanois et al., 2022, 2019).

Targeted Molecular Therapies

In addition to biologic therapies, targeted molecular therapies are gaining attention in OA treatment. These therapies aim to inhibit specific molecules involved in cartilage degradation, joint inflammation, and bone remodeling. For example, matrix metalloproteinases (MMPs) and aggrecanases, which are enzymes responsible for degrading cartilage, are key targets in OA research. The development of selective inhibitors targeting these enzymes could help to slow or even reverse the loss of cartilage, which is a hallmark of OA (Griffin and Scanzello, 2019). Similarly, RANKL inhibitors, which prevent the activation of osteoclasts and reduce bone resorption, are being investigated for their potential to preserve subchondral bone integrity in OA. Another promising target is Wnt/β-catenin signaling, which is involved in both cartilage degradation and bone remodeling in OA. Inhibiting this pathway could reduce inflammation and promote cartilage repair. Several small molecules and monoclonal antibodies targeting Wnt/β-catenin signaling are currently in preclinical and clinical development (Winthrop et al., 2023; Zhou et al., 2022).

Combination Therapies

The complexity of OA pathology, which involves joint inflammation, cartilage degeneration, and subchondral bone changes, suggests that a multi-faceted treatment approach may be more effective than single-target therapies. As such, combination therapies are gaining traction as a way to address the various aspects of OA simultaneously. For instance, combining stem cell therapy with gene therapy or PRP with anti-inflammatory agents may enhance the regenerative potential while controlling inflammation and preventing further joint damage. Emerging and experimental therapies in OA, including regenerative medicine, gene therapy, biologics, and targeted molecular therapies, are offering new hope for patients with this debilitating condition. While clinical outcomes have varied, ongoing research and the development of more refined treatment strategies, including combination therapies, hold the potential to significantly improve OA management (Park and Lee, 2022). As the understanding of OA pathophysiology deepens, the future of OA treatment is likely to become increasingly personalized, with therapies tailored to the individual patient's disease profile. Ultimately, these novel therapeutic approaches may pave the way for disease-modifying treatments that can not only alleviate symptoms but also slow or halt the progression of OA (Wan et al., 2022; Youn et al., 2023).

Osteoarthritis (OA) is a highly prevalent and debilitating joint disorder characterized by the progressive degeneration of articular cartilage, subchondral bone remodeling, and synovial inflammation. It is one of the leading causes of disability worldwide, particularly among aging populations. OA's multifactorial nature, involving a combination of genetic, environmental, mechanical, and inflammatory factors, complicates its management (Ying et al., 2023). Although current treatments primarily focus on symptom relief, such as pain control and joint function improvement, they fail to modify the disease course. This highlights the urgent need for innovative approaches that go beyond traditional methods to address the underlying mechanisms of OA. One such promising avenue is personalized medicine, which aims to tailor treatment strategies based on individual patient characteristics, thereby enhancing therapeutic outcomes and minimizing adverse effects (Reza et al., 2021).

Genetic and Molecular Insights in OA Pathogenesis

Recent advances in the genetic and molecular understanding of OA have paved the way for personalized medicine. A growing body of evidence suggests that OA is influenced by both genetic predispositions and environmental factors. Genetic studies have identified several susceptibility loci, such as variations in the COL2A1, GDF5, and MMP13 genes that are associated with an increased risk of developing OA, particularly in weight-bearing joints like the knee and hip. These findings suggest that personalized treatment strategies could benefit from genetic profiling, allowing clinicians to identify individuals at higher risk and implement early interventions aimed at preventing or slowing disease progression (Marshall et al., 2018; Takahata et al., 2022).

The molecular mechanisms underlying OA are also highly complex and variable among patients. Inflammatory cytokines, such as IL-1, TNF-α, and IL-6, play a critical role in the pathogenesis by promoting cartilage degradation, synovial inflammation, and subchondral bone changes (Mobasheri et al., 2019; Shen et al., 2014). Additionally, alterations in the extracellular matrix (ECM), including the breakdown of collagen and aggrecan, further contribute to joint

degeneration. Personalized medicine in OA could involve identifying patients with specific molecular and inflammatory profiles and targeting these pathways using tailored pharmacologic agents or biologics that block key inflammatory mediators. For example, targeting IL-1 with monoclonal antibodies (e.g., canakinumab) has shown promise in clinical trials and could be an effective strategy for individuals with elevated IL-1 levels (Guilak et al., 2018; Pérez-García et al., 2020).

Diagnostic Tools and Biomarkers for Personalized Treatment

A major challenge in OA management is the lack of reliable biomarkers that can predict disease progression, identify high-risk individuals, and monitor treatment efficacy. In personalized medicine, advanced diagnostic tools and biomarkers are crucial for accurate patient stratification. Imaging techniques, such as magnetic resonance imaging (MRI) and ultrasound, allow for the assessment of joint structure and cartilage integrity. Furthermore, biomarkers in blood and synovial fluid, such as collagenase or cartilage oligomeric matrix protein (COMP), can provide valuable insights into the rate of cartilage degradation and the presence of inflammation, aiding in the identification of patients who may benefit from specific interventions (Mobasheri et al., 2017; Ratneswaran et al., 2020).

The use of personalized biomarkers extends beyond diagnostic purposes. They can also play a key role in predicting response to treatment. For instance, certain patients may respond better to nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroid injections, while others may benefit more from intra-articular hyaluronic acid or platelet-rich plasma (PRP) injections, depending on the severity of inflammation or cartilage damage. Genetic profiling, in combination with clinical biomarkers, can further refine treatment regimens and optimize outcomes (Bansal et al., 2021; Meregawa and Liando, 2023).

The Role of Regenerative Medicine in OA

One of the most exciting frontiers in personalized medicine for OA is regenerative therapies. These therapies aim to repair or regenerate damaged cartilage and reverse the degenerative changes in OA-affected joints. Stem cell therapies, particularly those involving mesenchymal stem cells (MSCs), have garnered significant attention due to their potential to regenerate damaged tissues and modulate the inflammatory environment within the joint. Recent clinical trials have demonstrated promising results, with MSC injections improving cartilage repair and reducing pain and inflammation in OA patients (Gherghel et al., 2023; Shegos and Chaudhry, 2022).

Moreover, gene therapy holds the potential to correct underlying molecular defects or promote cartilage regeneration by introducing genes that stimulate chondrocyte proliferation or ECM production. These approaches can be personalized based on an individual's genetic profile, allowing for more targeted and effective interventions. Personalized regenerative medicine could also include tissue engineering, where scaffolds combined with growth factors and stem cells are used to rebuild damaged cartilage (Attri et al., 2023; Lana et al., 2023).

The personalized medicine in OA lies in the integration of omics technologies such as genomics, proteomics, and metabolomics-with advanced imaging, clinical data, and patient-reported outcomes. Such integration will allow for more precise identification of disease subtypes and risk factors, leading to highly tailored treatment plans. Furthermore, artificial intelligence (AI) and machine learning algorithms could assist clinicians in predicting disease progression and optimizing therapeutic strategies based on large datasets, including genetic information, biomarkers, and clinical parameters (Lana et al., 2023). As our understanding of OA's genetic and molecular underpinnings expands, and as diagnostic and therapeutic tools become more refined, personalized medicine will increasingly become a cornerstone in the management of OA. By focusing on individualized treatment strategies that address the unique biological characteristics of each patient, personalized medicine holds the potential to revolutionize the care of OA patients, improving both the effectiveness of interventions and the overall patient experience (Gherghel et al., 2023; Lana et al., 2023). The personalized medicine represents a paradigm shift in the management of osteoarthritis, offering the promise of more effective, targeted, and patient-centered therapies. With ongoing advances in genetics, biomarkers, and regenerative therapies, the future of OA treatment looks promising, moving us closer to a more individualized approach to this challenging and complex disease (Everts et al., 2020; Shamim et al., 2023).

7. Future Directions and Conclusion

The future of osteoarthritis (OA) research lies in a deeper understanding of its complex pathophysiology, improved diagnostic methods, and the development of more effective and targeted therapeutic strategies. A key area for future investigation is the identification and validation of novel biomarkers that can detect early-stage OA, predict disease progression, and help in stratifying patients for personalized treatment approaches (Kehayova et al., 2023). The integration of multi-omics technologies (genomics, proteomics, metabolomics) will likely lead to the discovery of novel biomarkers, enhancing diagnostic accuracy and facilitating individualized management strategies. Regenerative medicine, including stem cell-based therapies, gene therapy, and tissue engineering, represents an exciting frontier in OA treatment. Future studies will focus on optimizing the efficacy of these therapies in repairing damaged cartilage, restoring joint function, and preventing disease progression. Additionally, the application of gene-editing tools, such as CRISPR-Cas9, could provide a novel approach to modifying the underlying genetic and epigenetic factors contributing to OA (Liu et al., 2023).

Moreover, the role of inflammation in OA is being increasingly recognized, and future research may lead to the development of biologic therapies that target specific inflammatory cytokines and pathways involved in the disease. The exploration of combination therapies, including traditional pharmacological agents with regenerative treatments, may offer synergistic effects to halt or reverse cartilage degeneration (Kumar et al., 2023; Zhang et al., 2023). Lastly, advancements in artificial intelligence (AI) and machine learning hold promise for refining diagnostic processes and predicting treatment responses, potentially revolutionizing clinical decision-making and improving long-term outcomes for OA patients. These innovations are poised to drive the next generation of OA therapies and personalized medicine (Wang et al., 2023).

Osteoarthritis (OA) remains a significant global health challenge, characterized by a complex interplay of mechanical, biochemical, and genetic factors that drive cartilage degeneration, subchondral bone remodeling, and synovial inflammation. Despite extensive research, the underlying pathophysiological mechanisms of OA remain incompletely understood, particularly regarding the role of chondrocyte dysfunction, extracellular matrix degradation, and the inflammatory cytokine network. Recent advances have illuminated key molecular pathways involved in OA progression, such as the involvement of matrix metalloproteinases, pro-inflammatory mediators like IL-1 and TNF-α, and the growing recognition of OA as a whole-joint disease rather than merely a cartilage disorder (Shabbir et al., 2024). In terms of diagnosis, while radiographic imaging remains foundational, the integration of advanced imaging modalities such as MRI and the identification of biomarkers for early disease detection are poised to improve clinical outcomes. These innovations allow for earlier intervention and better stratification of patients, enabling personalized therapeutic approaches. Therapeutically, current interventions primarily focus on symptomatic relief, with limited success in altering disease progression (Atukorala and Hunter, 2023). However, emerging strategies such as regenerative medicine, including stem cell therapy, gene therapy, and tissue engineering, show significant promise in restoring cartilage function and halting OA progression. Additionally, biologic therapies targeting specific inflammatory pathways offer new avenues for disease modification. As research continues to elucidate the molecular mechanisms underlying OA, future treatments may offer more effective and individualized approaches, improving long-term patient outcomes and quality of life (Angelini et al., 2022; Dou et al., 2023).

References

Abu-Seida, A.M., 2015. Regenerative therapy for equine osteoarthritis: A concise review. Asian Journal of Animal and Veterinary Advances. https://doi.org/10.3923/ajava.2015.500.508

Ali, A., 2021. Pathophysiology of osteoarthritis and Current Treatment. Zagazig Veterinary Journal. https://doi.org/10.21608/zvjz.2021.40197.1117

Amano, K., Huebner, J.L., Stabler, T. V., Tanaka, M., McCulloch, C.E., Lobach, I., Lane, N.E., Kraus, V.B., Ma, C.B., Li, X., 2018. Synovial Fluid Profile at the Time of Anterior Cruciate Ligament Reconstruction and Its Association With Cartilage Matrix Composition 3 Years After Surgery. American Journal of Sports Medicine. https://doi.org/10.1177/0363546517749834

Angelini, F., Widera, P., Mobasheri, A., Blair, J., Struglics, A., Uebelhoer, M., Henrotin, Y., Marijnissen, A.C.A., Kloppenburg, M., Blanco, F.J., Haugen, I.K., Berenbaum, F., Ladel, C., Larkin, J., Bay-Jensen, A.C., Bacardit, J., 2022. Osteoarthritis endotype discovery via clustering of biochemical marker data. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2021-221763

Anthony, C.A., Rojas, E., Glass, N., Keffala, V., Noiseux, N., Elkins, J., Brown, T.S., Bedard, N.A., 2022. A Psycholgical Intervention Delivered by Automated Mobile Phone Messaging Stabilized Hip and Knee Function During the COVID-19 Pandemic: A Randomized Controlled Trial. Journal of Arthroplasty. https://doi.org/10.1016/j.arth.2021.12.006

Attri, D.S., Rathour, A., Ray, R.K., Kumar, V., 2023. Formulation and evaluation of hydrogel for topical drug delivery of Zingiber officinale Rosc . and Withania somnifera (L .) Dunal to increase the bioavailability of oils for the treatment of arthritis 12, 1–10.

Atukorala, I., Hunter, D.J., 2023. A review of quality-of-life in elderly osteoarthritis. Expert Review of Pharmacoeconomics and Outcomes Research. https://doi.org/10.1080/14737167.2023.2181791

Banjar, M., Horiuchi, S., Gedeon, D.N., Yoshioka, H., 2022. Review of Quantitative Knee Articular Cartilage MR Imaging. Magnetic Resonance in Medical Sciences. https://doi.org/10.2463/mrms.rev.2021-0052

Bansal, H., Leon, J., Pont, J.L., Wilson, D.A., Bansal, A., Agarwal, D., Preoteasa, I., 2021. Platelet-rich plasma (PRP) in osteoarthritis (OA) knee: Correct dose critical for long term clinical efficacy. Scientific Reports. https://doi.org/10.1038/s41598-021-83025-2

Bin, G., Jinmin, L., Cong, T., Yuchen, T., Xiaohui, Z., Yayi, X., 2023. Surgical interventions for symptomatic knee osteoarthritis: a network meta-analysis of randomized control trials. BMC Musculoskeletal Disorders. https://doi.org/10.1186/s12891-023-06403-z

Blanco, F.J., 2014. Osteoarthritis year in review 2014: We need more biochemical biomarkers in qualification phase. Osteoarthritis and Cartilage. https://doi.org/10.1016/j.joca.2014.09.009

Burke, J., Hunter, M., Kolhe, R., Isales, C., Hamrick, M., Fulzele, S., 2016. Therapeutic potential of mesenchymal stem cell based therapy for osteoarthritis. Clinical and Translational Medicine. https://doi.org/10.1186/s40169-016-0112-7

Chen, J., 2022. Recent Development of Biomaterials Combined with Mesenchymal Stem Cells as a Strategy in Cartilage Regeneration. International Journal of Translational Medicine. https://doi.org/10.3390/ijtm2030035

Coaccioli, S., Sarzi-Puttini, P., Zis, P., Rinonapoli, G., Varrassi, G., 2022. Osteoarthritis: New Insight on Its Pathophysiology. Journal of Clinical Medicine. https://doi.org/10.3390/jcm11206013

Costa, D., Cruz, E.B., Lopes, D.G., da Silva, C.N., Henriques, A.R., Luis, D., Branco, J., Canhão, H., Rodrigues, A.M., 2023. Prevalence of and factors associated with unmanageable pain levels in people with knee or hip osteoarthritis: a cross-sectional population-based study. BMC Musculoskeletal Disorders. https://doi.org/10.1186/s12891-022-06110-1

Delanois, R.E., Etcheson, J.I., Sodhi, N., Henn, R.F., Gwam, C.U., George, N.E., Mont, M.A., 2019. Biologic Therapies for the Treatment of Knee Osteoarthritis. Journal of Arthroplasty. https://doi.org/10.1016/j.arth.2018.12.001

Delanois, R.E., Sax, O.C., Chen, Z., Cohen, J.M., Callahan, D.M., Mont, M.A., 2022. Biologic Therapies for the Treatment of Knee Osteoarthritis: An Updated Systematic Review. Journal of Arthroplasty. https://doi.org/10.1016/j.arth.2022.05.031

Dou, H., Wang, S., Hu, J., Song, J., Zhang, C., Wang, J., Xiao, L., 2023. Osteoarthritis models: From animals to tissue engineering. Journal of Tissue Engineering. https://doi.org/10.1177/20417314231172584

Dudaric, L., Dumic-Cule, I., Divjak, E., Cengic, T., Brkljacic, B., Ivanac, G., 2023. Bone Remodeling in Osteoarthritis—Biological and Radiological Aspects. Medicina (Lithuania). https://doi.org/10.3390/medicina59091613

Emanuel, K.S., Kellner, L.J., Peters, M.J.M., Haartmans, M.J.J., Hooijmans, M.T., Emans, P.J., 2022. The relation between the biochemical composition of knee articular cartilage and quantitative MRI: a systematic review and meta-analysis. Osteoarthritis and Cartilage. https://doi.org/10.1016/j.joca.2021.10.016

Everts, P., Onishi, K., Jayaram, P., Lana, J.F., Mautner, K., 2020. Platelet-rich plasma: New performance understandings and therapeutic considerations in 2020. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms21207794

Fan, X., Sun, A.R., Young, R.S.E., Afara, I.O., Hamilton, B.R., Ong, L.J.Y., Crawford, R., Prasadam, I., 2024. Spatial analysis of the osteoarthritis microenvironment: techniques, insights, and applications. Bone Research. https://doi.org/10.1038/s41413-023-00304-6

Gao, Y.H., Zhao, C.W., Liu, B., Dong, N., Ding, L., Li, Y.R., Liu, J.G., Feng, W., Qi, X., Jin, X.H., 2020. An update on the association between metabolic syndrome and osteoarthritis and on the potential role of leptin in osteoarthritis. Cytokine. https://doi.org/10.1016/j.cyto.2020.155043

Gherghel, R., Macovei, L.A., Burlui, M.A., Cardoneanu, A., Rezus, I.I., Mihai, I.R., Rezus, E., 2023. Osteoarthritis—The Role of Mesenchymal Stem Cells in Cartilage Regeneration. Applied Sciences (Switzerland). https://doi.org/10.3390/app131910617

Ghouri, A., Conaghan, P.G., 2019. Update on novel pharmacological therapies for osteoarthritis. Therapeutic Advances in Musculoskeletal Disease. https://doi.org/10.1177/1759720X19864492

Goldring, M.B., Berenbaum, F., 2015. Emerging targets in osteoarthritis therapy. Current Opinion in Pharmacology. https://doi.org/10.1016/j.coph.2015.03.004

Griffin, T.M., Scanzello, C.R., 2019. Innate inflammation and synovial macrophages in osteoarthritis pathophysiology. Clinical and experimental rheumatology.

Guilak, F., Nims, R.J., Dicks, A., Wu, C.L., Meulenbelt, I., 2018. Osteoarthritis as a disease of the cartilage pericellular matrix. Matrix Biology. https://doi.org/10.1016/j.matbio.2018.05.008

Hunter, D.J., March, L., Sambrook, P.N., 2002. Knee osteoarthritis: The influence of environmental factors. Clinical and Experimental Rheumatology.

Jang, S., Lee, K., Ju, J.H., 2021. Recent updates of diagnosis, pathophysiology, and treatment on osteoarthritis of the knee. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms22052619

Kangeswari, P., Murali, K., Arulappan, J., 2021. Effectiveness of Isometric Exercise and Counseling on Level of Pain Among Patients With Knee Osteoarthritis. SAGE Open Nursing. https://doi.org/10.1177/2377960821993515

Kardos, D., Marschall, B., Simon, M., Hornyák, I., Hinsenkamp, A., Kuten, O., Gyevnár, Z., Erdélyi, G., Bárdos, T., Paukovits, T.M., Magos, K., Béres, G., Szenthe, K., Bánáti, F., Szathmary, S., Nehrer, S., Lacza, Z., 2019. Investigation of cytokine changes in osteoarthritic knee joint tissues in response to hyperacute serum treatment. Cells. https://doi.org/10.3390/cells8080824

Kehayova, Y.S., Wilkinson, J.M., Rice, S.J., Loughlin, J., 2023. Osteoarthritis genetic risk acting on the galactosyltransferase gene COLGALT2 has opposing functional effects in articulating joint tissues. Arthritis Research and Therapy. https://doi.org/10.1186/s13075-023-03066-y

Kim, H., Seo, J., Lee, Y., Park, K., Perry, T.A., Arden, N.K., Mobasheri, A., Choi, H., 2022. The current state of the osteoarthritis drug development pipeline: a comprehensive narrative review of the present challenges and future opportunities. Therapeutic Advances in Musculoskeletal Disease. https://doi.org/10.1177/1759720X221085952

Kim, M., Rubab, A., Chan, W.C.W., Chan, D., 2023. Osteoarthritis year in review 2022: Genetics, genomics and epigenetics. Osteoarthritis and Cartilage. https://doi.org/10.1016/j.joca.2023.03.003

Köhler-Forsberg, O., Sylvia, L., Thase, M., Calabrese, J.R., Deckersbach, T., Tohen, M., Bowden, C.L., McInnis, M., Kocsis, J.H., Friedman, E.S., Ketter, T.A., McElroy, S., Shelton, R.C., Nierenberg, A.A., 2017. Nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol do not affect 6-month mood-stabilizing treatment outcome among 482 patients with bipolar disorder. Depression and Anxiety. https://doi.org/10.1002/da.22601

Kucharz, E.J., Kovalenko, V., Szántó, S., Bruyère, O., Cooper, C., Reginster, J.Y., 2016. A review of glucosamine for knee osteoarthritis: Why patented crystalline glucosamine sulfate should be differentiated from other glucosamines to maximize clinical outcomes. Current Medical

Research and Opinion. https://doi.org/10.1185/03007995.2016.1154521

Kumar, N., Kumar, B., Sisodia, V.K., Rathour, A., Roy, R.K., Kumar, V., 2023. Determination of antibacterial and anti-inflammatory effect of developed ointment formulation containing rosmarinic acid 12, 1–11.

Kumar, V., Ain, S., Kumar, B., Ain, Q., Gaurav, 2020. Optimization and evaluation of topical gel containing solid lipid nanoparticles loaded with luliconazole and its anti-fungal activity, in: International Journal of Pharmaceutical Research. pp. 2901–2912. https://doi.org/10.31838/ijpr/2020.SP2.169

Kumavat, R., Kumar, V., Malhotra, R., Pandit, H., Jones, E., Ponchel, F., Biswas, S., 2021. Biomarkers of Joint Damage in Osteoarthritis: Current Status and Future Directions. Mediators of Inflammation. https://doi.org/10.1155/2021/5574582

Lana, J.F., Purita, J., Everts, P.A., De Mendonça Neto, P.A.T., de Moraes Ferreira Jorge, D., Mosaner, T., Huber, S.C., Azzini, G.O.M., da Fonseca, L.F., Jeyaraman, M., Dallo, I., Santos, G.S., 2023. Platelet-Rich Plasma Power-Mix Gel (ppm)—An Orthobiologic Optimization Protocol Rich in Growth Factors and Fibrin. Gels. https://doi.org/10.3390/gels9070553

Lim, P.Q.X., Lithgow, M.J., Kaminski, M.R., Landorf, K.B., Menz, H.B., Munteanu, S.E., 2023. Efficacy of non-surgical interventions for midfoot osteoarthritis: a systematic review. Rheumatology International. https://doi.org/10.1007/s00296-023-05324-3

Linda Pertiwi, N.M., Jaya Kirana, N.L., 2023. Conventional Radiography of Grade III Knee Osteoarthritis: A Case Report. International Journal of Research and Review. https://doi.org/10.52403/ijrr.20231068

Liu, Y., Liu, P.D., Zhang, C.M., Liu, M.R., Wang, G.S., Li, P.C., Yang, Z.Q., 2023. Research progress and hotspots on macrophages in osteoarthritis: A bibliometric analysis from 2009 to 2022. Medicine (United States). https://doi.org/10.1097/MD.0000000000034642

Marshall, M., Watt, F.E., Vincent, T.L., Dziedzic, K., 2018. Hand osteoarthritis: clinical phenotypes, molecular mechanisms and disease management. Nature Reviews Rheumatology. https://doi.org/10.1038/s41584-018-0095-4

Mayet, A., Zablotski, Y., Roth, S.P., Brehm, W., Troillet, A., 2023. Systematic review and meta-analysis of positive long-term effects after intra-articular administration of orthobiologic therapeutics in horses with naturally occurring osteoarthritis. Frontiers in Veterinary Science. https://doi.org/10.3389/fvets.2023.1125695

Mehrani, Y., Rahimi Junqani, R., Morovati, S., Mehrani, H., Karimi, N., Ghasemi, S., 2023. The Importance of Neutrophils in Osteoarthritis: Current Concepts and Therapeutic Perspectives. Immuno. https://doi.org/10.3390/immuno3030017

Meregawa, P.F., Liando, I.A., 2023. Platelet Rich Plasma (PRP) Injection in Osteoarthritis (OA) Knee. International Journal of Health Sciences and Research. https://doi.org/10.52403/ijhsr.20230205

Mills, E.S., Becerra, J.A., Yensen, K., Bolia, I.K., Shontz, E.C., Kebaish, K.J., Dobitsch, A., Hasan, L.K., Haratian, A., Ong, C.D., Gross, J., Petrigliano, F.A., Weber, A.E., 2022. Current and Future Advanced Imaging Modalities for the Diagnosis of Early Osteoarthritis of the Hip. Orthopedic Research and Reviews. https://doi.org/10.2147/ORR.S357498

Mimpen, J.Y., Baldwin, M.J., Cribbs, A.P., Philpott, M., Carr, A.J., Dakin, S.G., Snelling, S.J.B., 2021. Interleukin-17A Causes Osteoarthritis-Like Transcriptional Changes in Human Osteoarthritis-Derived Chondrocytes and Synovial Fibroblasts In Vitro. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2021.676173

Mobasheri, A., Batt, M., 2016. An update on the pathophysiology of osteoarthritis. Annals of Physical and Rehabilitation Medicine. https://doi.org/10.1016/j.rehab.2016.07.004

Mobasheri, A., Bay-Jensen, A.C., Gualillo, O., Larkin, J., Levesque, M.C., Henrotin, Y., 2017. Soluble biochemical markers of osteoarthritis: Are we close to using them in clinical practice? Best Practice and Research: Clinical Rheumatology. https://doi.org/10.1016/j.berh.2018.07.002

Mobasheri, A., Saarakkala, S., Finnilä, M., Karsdal, M.A., Bay-Jensen, A.C., van Spil, W.E., 2019. Recent advances in understanding the phenotypes of osteoarthritis. F1000Research. https://doi.org/10.12688/f1000research.20575.1

Motta, F., Barone, E., Sica, A., Selmi, C., 2023. Inflammaging and Osteoarthritis. Clinical Reviews in Allergy and Immunology. https://doi.org/10.1007/s12016-022-08941-1

Neubauer, M., Moser, L., Neugebauer, J., Raudner, M., Wondrasch, B., Führer, M., Emprechtinger, R., Dammerer, D., Ljuhar, R., Salzlechner, C., Nehrer, S., 2023. Artificial-Intelligence-Aided Radiographic Diagnostic of Knee Osteoarthritis Leads to a Higher Association of Clinical Findings with Diagnostic Ratings. Journal of Clinical Medicine. https://doi.org/10.3390/jcm12030744

Nieboer, M.F., Reijman, M., Wesdorp, M.A., Bastiaansen-Jenniskens, Y.M., Meuffels, D.E., 2023. Improved Understanding of the Inflammatory Response in Synovial Fluid and Serum after Traumatic Knee Injury, Excluding Fractures of the Knee: A Systematic Review. Cartilage. https://doi.org/10.1177/19476035221141417

Nishimura, K., Uehara, K., Miura, T., Ohe, T., Tanaka, S., Morizaki, Y., 2021. Factors Associated With Surgical Intervention for Osteoarthritis of the Thumb Carpometacarpal Joint. Journal of Hand Surgery. https://doi.org/10.1016/j.jhsa.2021.01.009

Niu, X., Li, N., Du, Z., Li, X., 2023. Integrated gradient tissue-engineered osteochondral scaffolds:

Challenges, current efforts and future perspectives. Bioactive Materials. https://doi.org/10.1016/j.bioactmat.2022.06.011

O'Neill, T.W., Felson, D.T., 2018. Mechanisms of Osteoarthritis (OA) Pain. Current Osteoporosis Reports. https://doi.org/10.1007/s11914-018-0477-1

Oo, W.M., Hunter, D.J., 2022. Repurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs). Therapeutic Advances in Musculoskeletal Disease. https://doi.org/10.1177/1759720X221090297

Panikkar, M., Attia, E., Dardak, S., 2021. Osteoarthritis: A Review of Novel Treatments and Drug Targets. Cureus. https://doi.org/10.7759/cureus.20026

Paradis, V.B., 2021. Literature Review: Pengaruh Kinesio Taping Terhadap Penurunan Nyeri Penderita Osteoarthritis Knee Pada lansia. Fakultas Ilmu Kesehatan Universitas Muhammadiyah Malang.

Park, J., Lee, S.Y., 2022. A review of osteoarthritis signaling intervention using small-molecule inhibitors. Medicine (United States). https://doi.org/10.1097/MD.0000000000029501

Pérez-García, S., Carrión, M., Gutiérrez-Cañas, I., Villanueva-Romero, R., Castro, D., Martínez, C., González-álvaro, I., Blanco, F.J., Juarranz, Y., Gomariz, R.P., 2020. Profile of matrix-remodeling proteinases in osteoarthritis: Impact of fibronectin. Cells. https://doi.org/10.3390/cells9010040

Pérez Fraile, A., González-Cubero, E., Martínez-Flórez, S., Olivera, E.R., Villar-Suárez, V., 2023. Regenerative Medicine Applied to Musculoskeletal Diseases in Equines: A Systematic Review. Veterinary Sciences. https://doi.org/10.3390/vetsci10120666

Prevention, C. for D.C. and, 2018. Osteoarthritis (OA) | Basics | Arthritis | CDC. Osteoarthritis (OA).

Rabiei, M., Kashanian, S., Samavati, S.S., Derakhshankhah, H., Jamasb, S., McInnes, S.J.P., 2021. Nanotechnology application in drug delivery to osteoarthritis (OA), rheumatoid arthritis (RA), and osteoporosis (OSP). Journal of Drug Delivery Science and Technology. https://doi.org/10.1016/j.jddst.2020.102011

Ratneswaran, A., Rockel, J., Shestopaloff, K., Antflek, D., Kapoor, M., Baltzer, H., 2020. Evaluating cytokines as biomarkers for trapeziometacarpal osteoarthritis. Osteoarthritis and Cartilage. https://doi.org/10.1016/j.joca.2020.02.197

Reza, M.K., Shaphe, M.A., Qasheesh, M., Shah, M.N., Alghadir, A.H., Iqbal, A., 2021. Efficacy of specified manual therapies in combination with a supervised exercise protocol for managing pain intensity and functional disability in patients with knee osteoarthritis. Journal of Pain Research. https://doi.org/10.2147/JPR.S285297

Rizzo, M.G., Best, T.M., Huard, J., Philippon, M., Hornicek, F., Duan, Z., Griswold, A.J., Kaplan, L.D., Hare, J.M., Kouroupis, D., 2023. Therapeutic Perspectives for Inflammation and Senescence in Osteoarthritis Using Mesenchymal Stem Cells, Mesenchymal Stem Cell-Derived Extracellular Vesicles and Senolytic Agents. Cells. https://doi.org/10.3390/cells12101421

Sadri, B., Nouraein, S., Hossein-Khannazer, N., Mohammadi, J., Vosough, M., 2021. Current and novel theranostic modalities for knee osteoarthritis. Sechenov Medical Journal. https://doi.org/10.47093/2218-7332.2021.293.03

Salman, L.A., Ahmed, G., Dakin, S.G., Kendrick, B., Price, A., 2023. Osteoarthritis: a narrative review of molecular approaches to disease management. Arthritis Research and Therapy. https://doi.org/10.1186/s13075-023-03006-w

Schrenker, S., Gao, L., Cucchiarini, M., Madry, H., 2019. Future Aspects of Clinical Osteoarthritis Therapies in the Continuum of Translational Research. Zeitschrift fur Orthopadie und Unfallchirurgie. https://doi.org/10.1055/a-0806-8225

Schulze-Tanzil, G., 2021. Experimental therapeutics for the treatment of osteoarthritis. Journal of Experimental Pharmacology. https://doi.org/10.2147/JEP.S237479

Shabbir, M.A., Mehak, F., Khan, M.R., Ahmed, W., Nawaz, M.F., Hassoun, A., Bhat, Z.F., Aadil, R.M., 2024. Unraveling the role of natural functional oils in modulating osteoarthritis related complications. Critical Reviews in Food Science and Nutrition. https://doi.org/10.1080/10408398.2023.2176815

Shamim, A., Ali, A., Iqbal, Z., Mirza, M.A., Aqil, M., Kawish, S.M., Siddiqui, A., Kumar, V., Naseef, P.P., Alshadidi, A.A.F., Saheer Kuruniyan, M., 2023. Natural Medicine a Promising Candidate in Combating Microbial Biofilm. Antibiotics. https://doi.org/10.3390/antibiotics12020299

Shavlovskaya, O.A., Gromova, O.A., Kochish, A.Y., Yukhnovskaya, Y.D., Romanov, I.D., Bokova, I.A., 2023. Disease-modifying osteoarthritis drugs (DMOADs): new trends in osteoarthritis therapy. Farmakoekonomika. https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.207

Shegos, C.J., Chaudhry, A.F., 2022. A narrative review of mesenchymal stem cells effect on osteoarthritis. Annals of Joint. https://doi.org/10.21037/aoj-21-16

Shen, J., Li, S., Chen, D., 2014. TGF-β signaling and the development of osteoarthritis. Bone Research. https://doi.org/10.1038/boneres.2014.2

Shih, P.C., Lee, Y.H., Tsou, H.K., Cheng-Chung Wei, J., 2023. Recent targets of osteoarthritis research. Best Practice and Research: Clinical Rheumatology. https://doi.org/10.1016/j.berh.2023.101851

Sobhani, K., Li, J., Cortes, M., 2023. Nonsteroidal Anti-inflammatory Drugs (NSAIDs), in: First Aid Perioperative Ultrasound: Acute Pain Manual for Surgical Procedures. https://doi.org/10.1007/978-3-031-21291-8_8

Stanciugelu, S., Homorogan, C., Selaru, C., Patrascu, J., Patrascu, J., Stoica, R., Nitusca, D., Marian, C., 2022. Osteoarthritis and microRNAs: Do They Provide Novel Insights into the Pathophysiology of This Degenerative Disorder? Life. https://doi.org/10.3390/life12111914

Sun, A.R.J., Udduttula, A., Li, J., Liu, Y., Ren, P.G., Zhang, P., 2021. Cartilage tissue engineering for obesity-induced osteoarthritis: Physiology, challenges, and future prospects. Journal of Orthopaedic Translation. https://doi.org/10.1016/j.jot.2020.07.004

Takahata, Y., Hagino, H., Kimura, A., Urushizaki, M., Yamamoto, S., Wakamori, K., Murakami, T., Hata, K., Nishimura, R., 2022. Regulatory Mechanisms of Prg4 and Gdf5 Expression in Articular Cartilage and Functions in Osteoarthritis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms23094672

Tiulpin, A., Thevenot, J., Rahtu, E., Lehenkari, P., Saarakkala, S., 2018. Automatic knee osteoarthritis diagnosis from plain radiographs: A deep learning-based approach. Scientific Reports. https://doi.org/10.1038/s41598-018-20132-7

Traut, P., 2022. Clinical diagnostics, differential diagnostics, pathogenesis and stage model of arthrofibrosis. Unfallchirurgie (Germany). https://doi.org/10.1007/s00113-022-01237-1

Tudorachi, N.B., Totu, E.E., Fifere, A., Ardeleanu, V., Mocanu, V., Mircea, C., Isildak, I., Smilkov, K., Cărăuşu, E.M., 2021. The implication of reactive oxygen species and antioxidants in knee osteoarthritis. Antioxidants. https://doi.org/10.3390/antiox10060985

Wan, Y., Sun, W., Yang, J., Ren, J., Kou, Q., 2022. The comparison of curcuminoid formulations or its combination with conventional therapies versus conventional therapies alone for knee osteoarthritis. Clinical Rheumatology. https://doi.org/10.1007/s10067-022-06105-2

Wang, S., Yang, J., Xiang, R., Li, C., Li, J., Shen, X., Liu, W., Xu, X., 2023. Research and publication trends on knee osteoarthritis and cellular senescence: a bibliometric analysis. Frontiers in Physiology. https://doi.org/10.3389/fphys.2023.1269338

Watson, D.W., Iglesias, S.L., Vasarhelyi, E.M., Heinrichs, D.E., 2021. GraXRS-Dependent Resistance of Staphylococcus aureus to Human Osteoarthritic Synovial Fluid. mSphere. https://doi.org/10.1128/msphere.00143-21

Weber, A.E., Bolia, I.K., Trasolini, N.A., 2021. Biological strategies for osteoarthritis: from early diagnosis to treatment. International Orthopaedics. https://doi.org/10.1007/s00264-020-04838-w

Winthrop, K.L., Mease, P., Kerschbaumer, A., Voll, R.E., Breedveld, F.C., Smolen, J.S.,

Gottenberg, J.E., Baraliakos, X., Kiener, H.P., Aletaha, D., Isaacs, J.D., Buch, M.H., Crow, M.K., Kay, J., Crofford, L., van Vollenhoven, R.F., Ospelt, C., Siebert, S., Kloppenburg, M., McInnes, I.B., Huizinga, T.W.J., Gravallese, E.M., 2023. Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023. Annals of the Rheumatic Diseases. https://doi.org/10.1136/ard-2023-224916

Wu, J., Chen, X., 2021. Recent research progress of hip-preserving treatment for adolescents and adults with developmental dysplasia of the hip. Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery. https://doi.org/10.7507/1002-1892.202108073

Yao, Q., Wu, X., Tao, C., Gong, W., Chen, M., Qu, M., Zhong, Y., He, T., Chen, S., Xiao, G., 2023. Osteoarthritis: pathogenic signaling pathways and therapeutic targets. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-023-01330-w

Ying, H., Shen, C., Pan, R., Li, X., Chen, Y., 2023. Strategy insight: Mechanical properties of biomaterials' influence on hydrogel-mesenchymal stromal cell combination for osteoarthritis therapy. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2023.1152612

Youn, S., Choi, J.H., Kim, C., Kim, S.M., Choi, W.S., 2023. Efficacy and safety of diacerein and celecoxib combination therapy for knee osteoarthritis: A double-blind, randomized, placebo-controlled prospective study. Medicine (United States). https://doi.org/10.1097/MD.0000000000035317

Zhang, S., Wang, Y., Zhou, M., Jia, S., Liu, Y., Zhang, X., Tai, X., 2023. A bibliometric analysis of traditional Chinese non-pharmacological therapies in the treatment of knee osteoarthritis from 2012 to 2022. Frontiers in Neuroscience. https://doi.org/10.3389/fnins.2023.1097130

Zheng, L., Zhang, Z., Sheng, P., Mobasheri, A., 2021. The role of metabolism in chondrocyte dysfunction and the progression of osteoarthritis. Ageing Research Reviews. https://doi.org/10.1016/j.arr.2020.101249

Zhou, H., Shen, X., Yan, C., Xiong, W., Ma, Z., Tan, Z., Wang, J., Li, Y., Liu, J., Duan, A., Liu, F., 2022. Extracellular vesicles derived from human umbilical cord mesenchymal stem cells alleviate osteoarthritis of the knee in mice model by interacting with METTL3 to reduce m6A of NLRP3 in macrophage. Stem Cell Research and Therapy. https://doi.org/10.1186/s13287-022-03005-9